FDA, Pharma Need To Take Next Step In Alzheimer’s Imaging Tools
Even with consensus on a path forward for imaging agents to be validated for detection of amyloid-beta, there are still questions about the clinical utility of the agents and the potential path toward their use in diagnosis of, or prognosis for, Alzheimer's disease
You may also be interested in...
Autopsy is the gold standard for confirming a diagnosis of Alzheimer's disease and should be used as the standard of truth in studies of imaging agents hoping to gain approval for amyloid plaque detection, an FDA panel unanimously concluded
A little more than a week after an article published in The Lancet raised questions about the assumption that removing amyloid plaque is key to modifying Alzheimer's disease - an assumption upon which most drug makers are pinning their hopes - Wyeth, Lilly and Pfizer unveiled data on their respective agents at the International Conference on Alzheimer's Disease in Chicago
But study published in Lancet raises questions about efficacy of anti-amyloid therapy.